What is the Role of Cangrelor in Patients Undergoing PCI?

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and oral P2Y12 inhibitors is standard for preventing ischemic events post-PCI.
• Oral P2Y12 inhibitors have delayed onset of action in P2Y12-naïve patients, posing a risk during PCI.
• Immediate and controllable platelet inhibition is crucial during percutaneous coronary intervention (PCI).

Purpose of the Study:

• To review the evidence and clinical applications of cangrelor, a novel intravenous P2Y12 inhibitor.
• To highlight cangrelor's role in providing immediate and controllable periprocedural platelet inhibition.
• To assess cangrelor's efficacy in reducing ischemic events during PCI.

Main Methods:

• Review of available clinical evidence and randomized trials on cangrelor use.
• Analysis of cangrelor's pharmacokinetic profile and its impact on platelet inhibition.
• Evaluation of cangrelor's safety and efficacy in the context of PCI procedures.

Main Results:

• Cangrelor demonstrates rapid onset of platelet inhibition due to its intravenous administration.
• Its short plasma half-life allows for effective and controllable periprocedural platelet inhibition.
• Large randomized trials indicate that cangrelor can reduce short-term ischemic events in PCI patients.

Conclusions:

• Cangrelor offers a valuable option for immediate P2Y12 inhibition in PCI patients, particularly those who are treatment-naïve.
• Its pharmacokinetic properties ensure controllable antiplatelet effects during the periprocedural period.
• Cangrelor can effectively mitigate short-term ischemic risks associated with PCI.